Acquiring Company
Concord Biotech Limited
Acquired Company
Celliimmune
AhmedabadManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
Concord Biotech Limited has successfully acquired Celliimmune for ₹66 Lakh to enhance its research in cancer therapeutics. This acquisition is part of Concord's strategic initiative to strengthen its position in the biotechnology sector. Celliimmune is known for its innovative approaches to cancer treatment, aligning with Concord's commitment to advanced therapeutics. This move is expected to propel both companies toward significant advancements in healthcare.
Who to call at Concord Biotech Limited, and when
When Concord Biotech Limited changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Concord Biotech Limited raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Concord Biotech Limited, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Concord Biotech Limited. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Concord Biotech Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Celliimmune?
Celliimmune was acquired by Concord Biotech Limited, based in Ahmedabad. The deal was reported on April 2, 2026. Concord Biotech Limited is a pharmaceutical company focused on research and development in biotechnology and advanced therapeutics. Concord Biotech Limited is privately held and operates in Manufacturing.
When did Concord Biotech Limited acquire Celliimmune?
Concord Biotech Limited's acquisition of Celliimmune was reported on April 2, 2026. Concord Biotech Limited has successfully acquired Celliimmune for ₹66 Lakh to enhance its research in cancer therapeutics. This acquisition is part of Concord's strategic initiative to strengthen its position in the biotechnology sector. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Celliimmune do?
Celliimmune specializes in cancer therapeutics research, aiming to develop innovative treatments. The company is committed to advancing the understanding of immune responses in cancer care. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.